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Abstract 
Background 
Rs6265 single nucleotide polymorphism, which influences brain-derived neurotrophic factor 
(BDNF) levels in the cortical and subcortical brain structures, may result in distinguished 
patterns of neural activation during a major depressive disorder (MDD) episode. Valine 
homozygotes with high levels of BDNF and methionine carriers with lower levels of BDNF 
may present specific neural correlates of MDD. In our study we have tested differences in 
blood oxygen level dependent (BOLD) signal between individuals with MDD and healthy 
controls for both allelic variants. 
Methods 
Individuals with MDD (N=37) and healthy controls (N=39) were genotyped for rs6265 and 
compared separately in each allelic variant for BOLD response in a functional magnetic 
resonance imaging experiment examining appraisal of emotional scenes. The two allelic 
variants were also compared separately for both individuals with MDD and healthy controls. 
Results 
In the homozygous valine group MDD was associated with decreased neural activation in 
areas responsible for cognitive appraisal of emotional scenes. In the methionine group MDD 
was related to increased activation in subcortical regions responsible for visceral reaction to 
emotional stimuli. During an MDD episode methionine carriers showed more activation in 
areas associated with cognitive appraisal of emotional information in comparison to valine 
homozygotes. 
Limitations 
Small sample size of healthy controls carrying methionine (N=8). 
Conclusion 
Our results suggest that allelic variations in the rs6265 gene lead to specific neural correlates 
of MDD which may be associated with different mechanisms of MDD in the two allelic 
groups. This may have potential importance for screening and treatment of patients.  
Introduction  
According to the neuroplasticity theory, brain-derived neurotrophic factor (BDNF)
*
, a peptide 
responsible for neuronal growth, plays a significant role in the pathogenesis of major 
depressive disorder (MDD) (Brunoni et al., 2008; Castren et al., 2007; Groves, 2007). BDNF 
is associated with plasticity and long-term synaptic connectivity in neural networks including 
the hippocampus, frontal lobes and striatum (Fossati et al., 2004). Altered secretion of BDNF 
observed in MDD can lead to long-term changes in these regions and consequently to 
cognitive symptoms characteristic of MDD (Fossati et al., 2004). An increase of BDNF level 
in specific neural areas can either promote or inhibit an antidepressant-like reaction (Castren 
et al., 2007; Groves, 2007).  
In rodents a direct injection of BDNF into the hippocampus diminishes depressive symptoms 
(Shirayama et al., 2002). Patients with MDD have reduced volumes of the hippocampus and 
frontal lobes (Dwivedi et al., 2003; Knable et al., 2004; Stockmeier et al., 2004), a sign of 
neuronal atrophy associated with lower levels of BDNF (Martinowich et al., 2007). One 
mechanism of action of therapies for MDD involves an increase of BDNF concentration in 
the hippocampus and frontal lobes (Brunoni et al., 2008). Conversely, a high concentration of 
BDNF in the midbrain is depressogenic and in rodents its reduction eliminates a depressive-
like behaviour (Berton et al., 2006; Eisch et al., 2003).  
Substituting valine by methionine in the Val66Met BDNF gene (rs6265) reduces activity-
dependent secretion of BDNF (Chen et al., 2004). This single-nucleotide polymorphism has 
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been previously associated with MDD (Binder and Scharfman, 2004). Carriers of at least one 
methionine show increased depressive behaviours (Schumacher et al., 2005), while 
displaying reduced volumes of frontal lobes (Nemoto et al., 2006; Pezawas et al., 2004) and 
hippocampus (Bueller et al., 2006; Pezawas et al., 2004), similar to patients with MDD 
(Koolschijn et al., 2009). Conversely, homozygous valine individuals score higher on the 
neuroticism scale, which is symptomatic of liability to MDD (Hunnerkopf et al., 2007). This 
suggests that a different neuronal pathway may lead to developing MDD in the two 
genotypes. 
Our study compares healthy controls and patients with MDD separately for both genotypes in 
neural correlates of emotional appraisal. Emotional appraisal is a part of the emotional 
regulation system monitoring approach-withdrawal behaviour, and in patients with MDD it 
could be altered in two ways. Firstly, according to emotional potentiation theory, patients 
with MDD would show a stronger visceral reaction during emotional appraisal (Bylsma et al., 
2008). Alternatively, according to emotion context insensitivity theory, patients with MDD 
would be less-reactive to emotional stimuli (Rottenberg et al., 2005). Both of these theories 
are associated with emotional flexibility connected with the role of BDNF in the brain. 
Methods 
Subjects 
Thirty-seven patients with MDD and thirty-nine healthy controls – matched for age, gender 
and handedness (all right-handed) – participated in the study. Written informed consent was 
obtained from all study participants. The study protocol was approved by the local ethics 
committee of Trinity College Dublin, Ireland, and prepared in accordance to the ethical 
standards of the Declaration of Helsinki.  
Participants with MDD were recruited from the Adelaide and Meath Hospital incorporating 
the National Children’s Hospital, Dublin, and from the St James’s Hospital, Dublin. The 
MDD diagnoses and lack of comorbidities for all the subjects were confirmed by the 
consensus of two consultant psychiatrists, one examining participants prior to the study and 
the other performing the structured Clinical Interview for Diagnostic Statistics Manual IV 
(First and Gibbon, 2004) two to three days prior to the assessment day. The medical 
exclusion criteria of the study included: previous or present head injury; a current or past 
psychiatric or neurological disease (apart from MDD in the case of the patient group); current 
medical disease influencing the nervous system; substance dependency. On the assessment 
day, participants’ health was verified via the Hamilton Depression Rating Scale (HDRS), 
Montgomery Asberg Depression Rating Scale (MADRS) and Beck Depression Inventory II 
(BDI-II). Depressed individuals differed significantly from healthy controls in all depression 
ratings (Lisiecka et al., 2013a). All healthy participants scored within the norm interval in 
HDRS, MDRS and BDI-II, and all subjects with MDD scored over the threshold 
characteristic for disease. Among patients, twelve were not medicated, thirteen were being 
treated with selective serotonin reuptake inhibitors and twelve with dual action substances. 
Five patients had had one previous episode of MDD, two patients had two previous episodes 
of MDD, while the remaining group were experiencing a first episode of MDD.  
Both patients with MDD and healthy controls were genotyped for the variants of the rs6265 
single nucleotide polymorphism (SNP). The Val66Met BDNF SNP (rs6265) was genotyped 
in the sample using a Taqman® SNP Genotyping Assay on a 7900HT Sequence Detection 
System (Applied Biosystems). The call rate for the Taqman genotyping was >95%, and all 
samples were in Hardy-Weinberg equilibrium (p>0.05). Along with the test samples, a 
number of HapMap CEU DNA sample positive controls (www.hapmap.org) and non-
template negative controls were genotyped for each SNP for quality control purposes. For 
positive controls, all genotypes were found to be concordant with the available online 
HapMap data. All non-template samples returned a negative result. As a result, participants 
were divided into three genotype groups: homozygous groups for methionine 
(bdnfmet66met) and valine alleles (bdnfval66val), and a heterozygous group carrying one 
methionine and one valine allele (bdnfval66met). Heterozygous individuals and subjects with 
two methionine alleles were combined into one group of methionine-carriers (bdnfval66met-
or-bdnfmet66met), as has been done in previous functional magnetic resonance imaging 
(fMRI) studies investigating Val66Met polymorphism (Lau et al., 2010; Montag et al., 2008) 
since methionine homozygotes are infrequent (Shimizu et al., 2004), and having at least one 
methionine allele is associated with susceptibility to MDD (Frodl et al., 2007).  
After the diagnostic and genotyping procedure, four groups of participants were 
distinguished: bdnfval66val patients with MDD (N=23; age=41.3±12.4 years; 17 females and 
6 males; HDRS=28.8±6.5; MADRS=29.6±7.4; BDI-II=30.7±12.2), bdnfval66met-or-
bdnfmet66met patients with MDD (N=14; age=41.9±8.1 years; 9 females and 5 males; 
HDRS=28.3±6.9; MADRS=29.4±4.9; BDI-II=35.7±10.6), bdnfval66val healthy controls 
(N=31; age=38.3±13.3 years; 19 females and 12 males; HDRS=2.6±2.4; MADRS=1.5±2.6; 
BDI-II=1.9±2.3), and bdnfval66met-or-bdnfmet66met healthy carriers (N=8; age=33.5±14.1 
years; 4 females and 4 males; HDRS=2.3±1.7; MADRS=3.3±4.8; BDI-II=4.3±4.9). The 
groups did not differ in age (p=0.369) or gender (p=0.623). They differed in all applied 
ratings of MDD (HDRS p<0.001; MADRS p<0.001; BDI-II p<0.001). However, there was 
no significant difference in the depression ratings between the two groups of healthy controls 
(HDRS p=0.998; MADRS p=0.82; BDI-II p=0.304) and between the two groups of MDD 
patients (HDRS p=0.988; MADRS p=1; BDI-II p=0.898). Furthermore, the two patients 
groups did not differ in the method of treatment (p=0.914) and the number of previous 
episodes of MDD (p=0.397). 
Design 
The study utilized a four sample design with bdnfval66val patients with MDD, 
bdnfval66met-or-bdnfmet66met patients with MDD, bdnfval66val healthy controls, and 
bdnfval66met-or-bdnfmet66met healthy controls as comparison groups. An event-related 
fMRI experiment measuring emotional appraisal of scenes with standardized ratings of 
emotional valence from International Affective Picture System (IAPS) was used during the 
recording of blood oxygen level dependent signals for each subject (Lang et al., 1999). The 
pictures selected for the study represented a broad range of emotional valence: from 1 (very 
negative) to 9 (very positive) on the IAPS valence scale, and were evenly distributed across 
the scale. To ensure that the chosen pictures had a consistent appraisal in the healthy 
population, those with minimal standard deviation in emotional valence and the ones judged 
similarly by men and women were selected for the task. The content of the pictures presented 
both people and objects. The details of the task are presented in Lisiecka et al. (Lisiecka et 
al., 2013b). 
Analysis 
A 4-group MANOVA was calculated to determine whether the groups differed in respect to 
reaction times (RTs) and accuracy measures. Subsequently, a post-hoc analysis was 
performed for participants’ RTs and accuracy. 
A 2x2 factorial analysis was performed with the diagnosis of MDD as the first and the 
Val66Met gene allele as the second factor. Participants’ age and gender were added as 
covariates of no interest. Contrasts were calculated to determine the differences between 
bdnfval66val healthy controls and bdnfval66met-or-bdnfmet66met healthy controls, between 
bdnfval66val healthy controls and bdnfval66val patients with MDD, between bdnfval66met-
or-bdnfmet66met healthy controls and bdnfval66met-or-bdnfmet66met patients with MDD, 
and between bdnfval66val patients with MDD and bdnfval66met-or-bdnfmet66met patients 
with MDD. The regions surviving the whole-brain cluster-level analysis with false discovery 
rate correction for multiple comparisons at p<0.05 are presented in results section. Automated 
anatomical labelling was used to localize the significant results in a standard stereotactic 
space (template – the Montreal Neurological Institute). 
Results 
Behavioural results 
Bdnfval66val healthy controls displayed accuracy of 83.7±8.1% with RT of 1.33±0.32 
seconds. For other groups the results were as followed: bdnfval66val patients with MDD – 
accuracy=74.8±13%, RT=1.5±0.32 seconds; bdnfval66met-or-bdnfmet66met patients with 
MDD – accuracy=76.9±10.5%, RT=1.64±0.58 seconds; bdnfval66met-or-bdnfmet66met 
healthy controls – accuracy=79.3±16.2%, RT=1.36±0.31 seconds. The only difference 
discovered by behavioural analysis was the diminished accuracy of bdnfval66val MDD 
patients in comparison to bdnfval66val healthy controls in emotional appraisal (p=0.025). 
fMRI results 
The bdnfval66val healthy controls, in comparison to the bdnfval66val patients with MDD, 
displayed more neural activation in the left angular gyrus, in the left middle occipital gyrus, 
in the right postcentral gyrus, in the right middle cingulate gyrus and in the right 
supramarginal gyrus (Fig. 1A, Tab. 1). The reversed comparison did not show any significant 
results. The bdnfval66met-or-bdnfmet66met patients with MDD displayed a heightened 
activation in contrast to the bdnfval66met-or-bdnfmet66met healthy controls in the left 
caudate nucleus (Fig. 1B, Tab. 1). The reversed comparison did not show any significant 
results. The bdnfval66met-or-bdnfmet66met healthy controls and the bdnfval66val healthy 
controls did not differ in neural correlates of emotional processing. The bdnfval66met-or-
bdnfmet66met patients with MDD experienced more neural activation than the bdnfval66val 
patients with MDD did in the right middle frontal gyrus and in the right superior frontal gyrus 
(Fig. 1C, Tab. 1). The reversed comparison did not show any significant results. 
Discussion 
We provide evidence that polymorphism in the Val66Met gene, previously associated with 
BDNF secretion (Chen et al., 2004) and vulnerability to MDD (Brunoni et al., 2008; Castren 
et al., 2007; Groves, 2007), modulates a difference between patients with MDD and healthy 
controls in correlates of emotional appraisal. The differences between patients with MDD and 
healthy controls follow unique pathways for each genotype.  
For the bdnfval66val group the differences between patients with MDD and healthy controls 
concentrate in the cortical compartment of the central nervous system, where patients with 
MDD experience reduced activation. It suggests a lowered top-down emotional regulation in 
the bdnfval66val individuals with MDD (Haldane and Frangou, 2006). Such disturbance 
typically results in a less efficient classification of emotional experiences, as observed in the 
behavioural responses of the bdnfval66val MDD patients. The areas where these patients 
displayed a decreased activation in comparison to the bdnfval66val healthy controls during 
emotional appraisal are involved in an emotional response to visual stimuli (angular and 
occipital gyri) (Hendler et al., 2001) and recognition of one’s own internal affective states 
(middle cingulate gyrus) (Kober et al., 2008). This suggests that in the bdnfval66val group 
major depressive disorder is characterized by disturbances in informative aspect of emotional 
processing. 
Conversely, the difference between patients with MDD and healthy controls in the 
bdnfval66met-or-bdnfmet66met group is localised in a sub-cortical region of striatum, where 
the patients show higher activation. Striatum participates in the visceral aspect of emotional 
experience (Jensen et al., 2003; Kober et al., 2008). This suggests that bdnfval66met-or-
bdnfmet66met patients with MDD experience stronger visceral reaction to emotional stimuli 
(Longstaff, 2005). The increase of activation in striatum (Banner et al., 2011) has been 
associated with vulnerability to MDD linked to methionine allele. A changed level of BDNF 
observed in the region can produce depressive-like symptoms (Berton et al., 2006; Eisch et 
al., 2003). This suggests that MDD in the bdnfval66met-or-bdnfmet66met group may be 
associated with an atypical distribution of BDNF in this area and thus prolonged stress 
reaction associated with the hypothalamic-pituitary-adrenal axis (Dawood et al., 2007; Praag 
et al., 2004).  
Finally, the Val66Met polymorphism distinguishes two groups of patients with MDD. In 
comparison to the bdnfval66val MDD patients, the bdnfval66met-or-bdnfmet66met MDD 
patients experienced an increased activation in the right dorsolateral prefrontal cortex 
(DLPFC). The DLPFC has a strong connection with BDNF but should not be activated 
during emotional appraisal (Berton et al., 2006; Eisch et al., 2003; Nemoto et al., 2006; 
Pezawas et al., 2004). However, its increased activation in the bdnfval66met-or-
bdnfmet66met MDD patients may further indicate their incorrect BDNF distribution or be a 
symptom of diminished top-down regulation in the bdnfval66val MDD patients.  
Interestingly, there was no difference observed in amygdalae, areas typically associated with 
emotional appraisal. However, the nature of our task (event-related) as well as the themes of 
visual stimuli used (combination of objects and people) could account for this result (Sergerie 
et al., 2008). 
Limitations 
Our analysis was performed as a sub-section of a larger study investigating the influence of 
the family history of depression on emotional processing in individuals with MDD and 
healthy controls (Lisiecka et al., 2013a). This is why the numbers of participants in the 
groups in the present analysis may not have been optimal. However, methionine-allele in 
rs6265 is rare in the human population and studies of the methionine carrying group often 
show a disproportion between numbers of individuals with methionine and valine alleles. 
Conclusion 
The BDNF gene has been shown to differentiate effectively between different sub-types of 
patients with MDD. This study reports neural differences in emotional appraisal between 
bdnfval66val patients with MDD and bdnfval66met-or-bdnfmet66met patients. The patients 
with two different genetic backgrounds differed in neither clinical features nor behavioural 
performance. However, the differences in emotional processing between the sub-types of 
patients with MDD suggest that the two groups follow unique trajectories towards MDD. 
This indicates the potential role genetic screening may play in choosing the appropriate 
treatment for different types of MDD, thus offering more effective treatment outcomes. 
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Figure legends 
Figure 1. Regions of differences in neural activation during emotional appraisal between A) 
HC-VAL and MDD-VAL, B) MDD-MET and HC-MET and C) MDD-MET and MDD-
VAL; FDR whole-brain corrected on cluster level with q<0.05. 
